Bohlen P - Search Results

1

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.

Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS. Klement G, et al. Among authors: bohlen p. J Clin Invest. 2000 Apr;105(8):R15-24. doi: 10.1172/JCI8829. J Clin Invest. 2000. PMID: 10772661 Free PMC article.

2

Complete inhibition of vascular endothelial growth factor (VEGF) activities with a bifunctional diabody directed against both VEGF kinase receptors, fms-like tyrosine kinase receptor and kinase insert domain-containing receptor.

Lu D, Jimenez X, Zhang H, Wu Y, Bohlen P, Witte L, Zhu Z. Lu D, et al. Among authors: bohlen p. Cancer Res. 2001 Oct 1;61(19):7002-8. Cancer Res. 2001. PMID: 11585724

3

Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2.

Kunkel P, Ulbricht U, Bohlen P, Brockmann MA, Fillbrandt R, Stavrou D, Westphal M, Lamszus K. Kunkel P, et al. Among authors: bohlen p. Cancer Res. 2001 Sep 15;61(18):6624-8. Cancer Res. 2001. PMID: 11559524

4

Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis.

Viloria-Petit A, Crombet T, Jothy S, Hicklin D, Bohlen P, Schlaeppi JM, Rak J, Kerbel RS. Viloria-Petit A, et al. Among authors: bohlen p. Cancer Res. 2001 Jul 1;61(13):5090-101. Cancer Res. 2001. PMID: 11431346

5

Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea.

Zimmermann RC, Hartman T, Bohlen P, Sauer MV, Kitajewski J. Zimmermann RC, et al. Among authors: bohlen p. Microvasc Res. 2001 Jul;62(1):15-25. doi: 10.1006/mvre.2001.2312. Microvasc Res. 2001. PMID: 11421657

6

Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts.

Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Kozin SV, et al. Among authors: bohlen p. Cancer Res. 2001 Jan 1;61(1):39-44. Cancer Res. 2001. PMID: 11196192

7

Identification of the residues in the extracellular region of KDR important for interaction with vascular endothelial growth factor and neutralizing anti-KDR antibodies.

Lu D, Kussie P, Pytowski B, Persaud K, Bohlen P, Witte L, Zhu Z. Lu D, et al. Among authors: bohlen p. J Biol Chem. 2000 May 12;275(19):14321-30. doi: 10.1074/jbc.275.19.14321. J Biol Chem. 2000. PMID: 10799512

8

Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.

Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ. Prewett M, et al. Among authors: bohlen p. Cancer Res. 1999 Oct 15;59(20):5209-18. Cancer Res. 1999. PMID: 10537299

9

Inhibition of vascular endothelial growth factor induced mitogenesis of human endothelial cells by a chimeric anti-kinase insert domain-containing receptor antibody.

Zhu Z, Lu D, Kotanides H, Santiago A, Jimenez X, Simcox T, Hicklin DJ, Bohlen P, Witte L. Zhu Z, et al. Among authors: bohlen p. Cancer Lett. 1999 Mar 1;136(2):203-13. doi: 10.1016/s0304-3835(98)00324-3. Cancer Lett. 1999. PMID: 10355750

10

Inhibition of vascular endothelial growth factor-induced receptor activation with anti-kinase insert domain-containing receptor single-chain antibodies from a phage display library.

Zhu Z, Rockwell P, Lu D, Kotanides H, Pytowski B, Hicklin DJ, Bohlen P, Witte L. Zhu Z, et al. Among authors: bohlen p. Cancer Res. 1998 Aug 1;58(15):3209-14. Cancer Res. 1998. PMID: 9699643

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results